Utilization of the CBP but not the p300 co-activator by human T-lymphotropic virus type-2 Tax for p53 inhibition

被引:19
作者
Meertens, L
Pise-Masison, C
Quere, N
Brady, J
Gessain, A
Mahieux, R
机构
[1] Inst Pasteur, Unite Edpidemiol & Physiopathol Virus Oncogenes, F-75724 Paris 15, France
[2] NCI, Virus Tumor Biol Sect, NIH, Bethesda, MD 20892 USA
关键词
HTLV; tax; p53; CBP/p300; NF-kappa B;
D O I
10.1038/sj.onc.1207719
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We previously reported, both in transfected cells and in human T-cell leukemia virus type-2 subtype B infected cells, that the viral transactivator Tax-2B protein could inhibit p53 functions. We have now investigated the mechanism through which Tax-2B represses p53 using GFPTax-2B fusion proteins. We present evidence that Tax-2B inhibition of p53 function is not linked to CREB/ ATF activation, but is uniquely correlated with the interaction of CREB binding protein (CBP), but not p300, with the C-terminus of Tax-2B. Wild type, but not a Tax-2B-M47 mutant, inhibits p53 function in adherent cells. We demonstrate that both Tax-2B and Tax-2B-M47 can bind p300, while Tax-2B-M47 is impaired for CBP binding. Importantly, transfection of increasing amounts of CBP but not p300 or p300/CBP-associated factor (P/CAF) could rescue p53 transcriptional activity in the presence of Tax-2B in nonlymphocytic cells. In lymphoid cells, Tax-2B mediated inhibition of p53 is correlated with the NF-kappaB pathway activation and could be prevented by the overexpression of an IkappaBalpha mutant. Given the similarities between the functional domains of CBP and p300, these results are intriguing and suggest that Tax-2B must bind the CR2 domain of CBP, but not that of p300 in order to repress p53.
引用
收藏
页码:5447 / 5458
页数:12
相关论文
共 57 条
[1]   DISTINCT REGIONS IN HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-I TAX MEDIATE INTERACTIONS WITH ACTIVATOR PROTEIN CREB AND BASAL TRANSCRIPTION FACTORS [J].
ADYA, N ;
GIAM, CZ .
JOURNAL OF VIROLOGY, 1995, 69 (03) :1834-1841
[2]   Aberrant expression and function of p53 in T-cells immortalized by HTLV-I Tax1 [J].
Akagi, T ;
Ono, H ;
Tsuchida, N ;
Shimotohno, K .
FEBS LETTERS, 1997, 406 (03) :263-266
[3]   Characterization of a nuclear export signal within the human T cell leukemia virus type I transactivator protein tax [J].
Alefantis, T ;
Barmak, K ;
Harhaj, EW ;
Grant, C ;
Wigdahl, B .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (24) :21814-21822
[4]   HTLV-1 Tax oncoprotein represses the p53-mediated trans-activation function through coactivator CBP sequestration [J].
Ariumi, Y ;
Kaida, A ;
Lin, JY ;
Hirota, M ;
Masui, O ;
Yamaoka, S ;
Taya, Y ;
Shimotohno, K .
ONCOGENE, 2000, 19 (12) :1491-1499
[5]   Differential transcriptional activation by human T-cell leukemia virus type 1 Tax mutants is mediated by distinct interactions with CREB binding protein and p300 [J].
Bex, F ;
Yin, MJ ;
Burny, A ;
Gaynor, RB .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (04) :2392-2405
[6]   The MHC class II transcriptional activator (CHTA) inhibits HTLV-2 viral replication by blocking the function of the viral transactivator Tax-2 [J].
Casoli, C ;
Barbaro, AD ;
Pilotti, E ;
Bertazzoni, U ;
Tosi, G ;
Accolla, RS .
BLOOD, 2004, 103 (03) :995-1001
[7]   P53 functional impairment and high p21(waf1/cip1) expression in human T-cell lymphotropic/leukemia virus type I-transformed T cells [J].
Cereseto, A ;
Diella, F ;
Mulloy, JC ;
Cara, A ;
Michieli, P ;
Grassmann, R ;
Franchini, G ;
Klotman, ME .
BLOOD, 1996, 88 (05) :1551-1560
[8]   Identification and characterization of a new and distinct molecular subtype of human T-Cell lymphotropic virus type 2 [J].
Eiraku, N ;
Novoa, P ;
Ferreira, MD ;
Monken, C ;
Ishak, R ;
Ferreira, OD ;
Zhu, SW ;
Lorenco, R ;
Ishak, M ;
Azvedo, V ;
Guerreiro, J ;
deOliveira, MP ;
Loureiro, P ;
Hammerschlak, N ;
Ijichi, S ;
Hall, WW .
JOURNAL OF VIROLOGY, 1996, 70 (03) :1481-1492
[9]   Human T-cell leukemia virus type 2 (HTLV-2) Tax protein transforms a rat fibroblast cell line but less efficiently than HTLV-1 Tax [J].
Endo, K ;
Hirata, A ;
Iwai, K ;
Sakurai, M ;
Fukushi, M ;
Oie, M ;
Higuchi, M ;
Hall, WW ;
Gejyo, F ;
Fujii, M .
JOURNAL OF VIROLOGY, 2002, 76 (06) :2648-2653
[10]  
Fouchard N, 1995, LEUKEMIA, V9, P2087